What one share of Outlook Therapeutics holds
We are a biopharmaceutical company that has developed ONS-5010/LYTENAVATM as the first ophthalmic formulation of bevacizumab approved by the European Commission in the European Union, or EU, and the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom, or UK, for use in adults for the treatment of wet age-related macular degeneration, or wet AMD.
Outlook Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.75 |
|---|---|
| Cash and investments | $0.06 |
| Debt | $0.05 |
| Book value | −$0.06 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | — | −$869.39 | $144.43 | −$595.15 | — | −$919.33 |
| 2016 | — | −$586.90 | $10.21 | −$432.98 | — | −$36.30 |
| 2017 | — | −$288.00 | $1.94 | −$105.13 | — | −$215.94 |
| 2018 | — | −$194.72 | $11.28 | −$145.25 | — | −$56.59 |
| 2019 | — | −$39.62 | $0.48 | −$35.98 | — | −$11.28 |
| 2020 | — | −$13.47 | — | — | — | $0.44 |
| 2021 | — | −$6.96 | — | — | — | $0.52 |
| 2022 | — | −$6.23 | — | — | — | $0.77 |
| 2023 | — | −$4.72 | — | — | — | −$1.11 |
| 2024 | — | −$4.06 | — | — | — | −$3.06 |
| 2025 | $0.04 | −$1.79 | — | — | — | −$0.60 |
Common questions about Outlook Therapeutics
How much does one share of Outlook Therapeutics earn?
Over the last 12 months, Outlook Therapeutics lost $0.75 for each share.
Does Outlook Therapeutics pay a dividend?
Outlook Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Outlook Therapeutics’s book value per share?
Outlook Therapeutics’s book value is negative (−$0.06 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Outlook Therapeutics have?
Each share of Outlook Therapeutics has $0.06 of cash and investments and $0.05 of debt, as of June 30, 2026.
Has Outlook Therapeutics bought back shares?
Outlook Therapeutics’s share count rose about 56980% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.